

Track record – Diseases – Neurosciences

Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands. van Boven JF, Novak A, Driessen MT, Boersma C, Boomsma MM, Postma MJ. *Drugs Aging*. 2014 Mar;*31*(3):193-201. doi: 10.1007/s40266-013-0150-4.

The proportional odds model is more efficient than the multinomial logistic model for network meta-analyses of ordered outcomes. Bouwmeester W, van Beurden-Tan C, Bennison C, Heeg B. *Value in health* 2014.

The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings. Kotsopoulos N, Connolly MP, Sobanski E, Postma MJ. *J Ment Health Policy Econ*. 2013 Mar;*16*(1):27-33.

Evaluating interventions to improve somatic health in severe mental illness: a systematic review. van Hasselt FM, Krabbe PF, van Ittersum DG, Postma MJ, Loonen AJ. *Acta Psychiatr Scand*. 2013 Oct;*128*(4):251-60. doi: 10.1111/acps.12096. Epub 2013 Feb 26.

Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes. Jentink J, Boersma C, de Jong-van den Berg LT, Postma MJ. *J Med Econ*. 2012;*15*(5):862-8. doi: 10.3111/13696998.2012.684366. Epub 2012 May 3.

Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson's disease. Postma MJ, Boersma C. *Expert Rev Clin Pharmacol*. 2012 Jan;*5*(1):1-4. doi: 10.1586/ecp.11.69. No abstract available.

The cost-effectiveness of paliperidone extended release in Spain. Treur M, Baca E, Bobes J, Cañas F, Salvador L, Gonzalez B, Heeg B. *Journal of Medical Economics* 2012;*15* Suppl 1:26-34

Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ. *Clin Ther*. 2010 Jan;*32*(1):108-18. doi: 10.1016/j.clinthera.2010.01.00

Cost Effectiveness of Long-Acting Risperidone in Sweden. Hensen M, Heeg B, Lothgren M, van Hout B. *Applied Health Economics and Health Policy* 01/2010; *8*(5):327-341.

Cost effectiveness of long-acting risperidone in Sweden. Hensen M, Heeg B, Löthgren M, van Hout B. *Applied Health Economics and Health Policy* 01/2010; *8*(5):327-41.

A conceptual framework that captures the multidimensional aspect of adherence in a health economic model: an application in chronic non-malignant pain management. Treur M, Houwing N, Heeg B, Kristanto P, Botteman M, Vo P, Marx S, Lockhart E, Van Hout B. *AD3. Value in Health* 01/2010; *13*(7).

Canadian cost-effectiveness analysis of long-acting risperidone versus oral atypical and conventional depot antipsychotics in patients with schizophrenia at high-risk of non-compliance: updated based on new clinical data. Lam A, Heeg B. *Pmh55 Value in Health* 01/2010; *13*(3).

Discrete event simulation model in major depressive disorder: life-time health outcomes of adjunctive atypical antipsychotics. Treur M, Pitchot W, Postema R, Loze JY, Heeg B, Drost P. *PMH11. Value in Health* 01/2010; *13*(3)

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. Treur M, Heeg B, Möller HJ, Schmeding A, van Hout B. *BMC Health Services Research* 03/2009; *9*:32

Predictors for starting depot administration of risperidone in chronic users of antipsychotics. Vehof J, Postma MJ, Bruggeman R, De Jong-Van Den Berg LT, Van Den Berg PB, Stolk RP, Burger H. *J Clin Psychopharmacol*. 2008 Dec;*28*(6):625-30. doi: 10.1097/JCP.0b013e31818a6d10.

Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder. Klok RM, Al Hadithy AF, van Schayk NP, Antonisse AJ, Caro JJ, Brouwers JR, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2007 Oct;*7*(5):459-67. doi: 10.1586/14737167.7.5.459.